Month: March 2020

Financial highlightsCHF 21.9 million cash & cash equivalents, trade and other receivables as at December 31, 2019Revenues increased to CHF 2.6 millionNet operating costs decreased to CHF 13.5 millionOperational highlightsU.S. & European product sales increased fivefold compared to last yearRaised CHF 12.5 million to advance product pipeline and commercialization of MagnetOsSCHLIEREN (ZURICH), Switzerland, March 26, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences successfully delivered on its targets in 2019, increasing sales of MagnetOs fivefold and confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration.Kuros raised gross proceeds of CHF 12.5 million from a capital increase to advance its pipeline, in particular the Phase II clinical...

Highlights:Little Green Pharma completes commissioning of cultivation facility expansion on time and on budgetExpanded cultivation facility will allow production of up to 110,000 bottles of medicinal cannabis oil per annum, approximately 10 times current capacityFirst planting targeted for Q2CY2020, subject to Office of Drug Control permittingExpansion of LGP’s cultivation capacity will assist in fulfilling sales agreements for the German and UK marketsMONTREAL, March 26, 2020 (GLOBE NEWSWIRE) —  ELIXXER, LTD. (TSX.V: ELXR.  OTCQB: ELIXF GR: 2LQA) (“ELXR” or the “Company”)”) is pleased to announce that Little Green Pharma has completed the commissioning of its expanded cultivation facility in Western Australia.The facility will operate under its expanded Medicinal Cannabis Licence, which was granted by the Office of Drug Control...

Due to the emergency situation in the Baltic States until at least May 1, 2020, EfTEN Real Estate Fund III AS announces that the Fund’s general meeting is expected to take place in June this year. The Fund will announce the exact time, place and agenda of the general meeting through a stock exchange release and the newspaper “Postimees” by May 31th, 2020 at the latest. The Fund Manager is managing the potentially negative economic impacts and mitigating the risks due to the COVID-19 and the state of an emergency on a daily basis, and if necessary, enters into additional temporary lease agreements with tenants. The goal of the Fund is to keep a close contact with tenants, find solutions to encountered difficulties, and to minimize as much as possible monthly operational costs of the Fund until the end of the state of an emergency....

Seoses Balti riikides välja kuulutatud eriolukorra jätkumisega vähemalt 1. maini 2020 teatab EfTEN Real Estate Fund III AS, et fondi üldkoosolek toimub eeldatavalt käesoleva aasta juunis. Täpsema üldkoosoleku toimumise aja, koha ning päevakorra annab fond börsiteate ja ajalehe „Postimees“ kaudu teada hiljemalt 31. maiks 2020. Fondi valitseja eeldab, et juuni kuuks on täpsemalt selgunud eriolukorrast tulenevad lühiajalised ja pikaajalised majanduslikud mõjud fondi varadele ning selginenud Balti riikide majanduskeskkonna väljavaated. Fondi valitseja tegeleb igapäevaselt COVID-19 ja eriolukorra kehtestamisest tulenevate potentsiaalselt negatiivsete majanduslike mõjude ja riskide maandamisega ning sõlmib vajadusel ajutisi lisakokkuleppeid üürnikega. Eesmärk on olla tihedas suhtluses meie üürnikega, leida lahendusi kiirelt tekkinud raskuste...

Press ReleaseGosselies, Belgium, 26 March 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it is further strengthening its management team with the appointment of Stefanos Theoharis, PhD, as Chief Business Officer (CBO).Stefanos will be responsible for the company’s corporate development activities and executing its business strategy. His immediate priorities will be concentrating on partnering Bone Therapeutics products and in-licensing innovations. He will also further develop the commercial strategies for the product portfolio and cell therapy platform.“At this stage of the development of Bone Therapeutics, it is very important to appoint a proven executive with a high level of business experience...

Communiqué de presseGosselies, Belgique, le 26 mars 2020, 07h00 CET – BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires et biologiques innovantes répondant à d’importants besoins médicaux non satisfaits dans les domaines de l’orthopédie et des maladies osseuses, annonce aujourd’hui le renforcement de son équipe de direction par la nomination de Stefanos Theoharis, PhD, au poste de Directeur Commercial (Chief Business Officer – CBO).Stefanos sera responsable des activités de développement de l’entreprise et de l’exécution de sa stratégie commerciale. Ses priorités immédiates consisteront principalement en la négociation d’accords de partenariat portant sur les produits de Bone Therapeutics et la recherche d’innovations...

Bollène, March 26, 2020 – 07 :00 a.m. (CET)Press Release2019 ANNUAL RESULTS 2019 Turnover: €31.8m (+0.1% YoY),2019 Order Book: €34.8m (+25% YoY)2019 EBITDA: -€0.1m* vs €0.67m in 2018      ·2019 Operating Results: -€1.4mA transitional year 2019 with positive developments for 2020: +13% growth in H2 after a difficult H12020: Focus on profitability and growthTo this day, impact of Covid-19 still minimal on customers’ global production and delivery requirementsRestructuring of Egide SA completed in December 2019                         * Excluding restructuring      The results presented below are unaudited consolidated financial statements for 2019 but reviewed by the Audit Committee on March 24, 2020; certification of accounts is expected in the coming weeks.CONSOLIDATED FINANCIALS 2019REVENUEEgide Group’s unaudited consolidated...

Bollène, le 26 mars 2020 – 07 :00 (CET)Communiqué de presseRESULTATS ANNUELS 2019 Chiffre d’affaires 2019 : 31,8 millions d’euros (+0,1% /2018)Carnet de commandes 2019 : 34,8 millions d’euros (+25% /2018)Excédent Brut d’Exploitation 2019 : -0,1 million d’euros* contre 0,7 million d’euros en 2018Résultat d’exploitation 2019 : -1.4m€2019 : une année de transition avec des perspectives positives pour 2020 : +13% de croissance au second semestre après un premier semestre difficileFocus 2020 : rentabilité et croissanceÀ ce jour, l’impact de la crise liée au Covid-19 reste minime sur les demandes de production et de livraison des clients à l’échelle mondialeRestructuration d’Egide SA achevée en décembre 2019                         * hors restructurationLes résultats présentés ci-dessous...

Strong order intake and record backlog across all business linesSignificantly strengthened balance sheetLouvain-La-Neuve, Belgium, 26 March 2020 – IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated annual results for the 2019 financial year.* Dosimetry numbers (including RadioMed) re-integrated, following the decision in 2019 to retain the business** RadioMed numbers integrated for 11 months following its disposal in December 2019IFRS 16 – Leases became effective on January 1, 2019. The effect of this accounting standard at December 31, 2019 is an improvement of REBIT by EUR 0.3m and of REBITDA by EUR 4.9m. The impact on the net result is immaterialOlivier Legrain, Chief Executive Officer of IBA commented: “At IBA’s core...